Line Stensig Lynggaard

Line Stensig Lynggaard

Auto-generated profile, based on publicly available information

Line Stensig Lynggaard

Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
LLLsl Line Stensig Lynggaard
Lsl Line Stensig Lynggaard
CRCecilie Utke Rank
Cecilie Utke Rank
SHStefan Nygaard Hansen
Stefan Nygaard Hansen
SHSofie Gottschalk Højfeldt
Sofie Gottschalk Højfeldt
LHLouise Tram Henriksen
Louise Tram Henriksen
BABirgitte Klug Albertsen
Birgitte Klug Albertsen
Asparaginase treatment is a mainstay in contemporary treatment of acute lymphoblastic leukemia (ALL), but substantial asparaginase-related toxicity may lead to jeopardized protocol compliance and compromises survival. We investigated the association between risk of asparaginase-associated toxicities (AspTox) and asparaginase enzyme activity (AEA) levels in 1155 children aged 1.0 to 17.9 years, diagnosed with ALL between July 2008 and March 2016, and treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol. Patients with ≥2 blood samples for AEA measurement drawn 14 ± 2 days after asparaginase administration were included (6944 trough values). AEA was measurable (or >0 IU/L) in 955 patients, whereas 200 patients (17.3%) had asparaginase inactivation and few AspTox recorded. A time-dependent multiple Cox model of time to any first asparaginase-associated toxicity adjusted for sex and age was used. For patients with measurable AEA, we found a hazard ratio (HR) of 1.17 per 100 IU/L increase in median AEA (95% confidence interval [CI], 0.98-1.41; P = .09). For pancreatitis, thromboembolism, and osteonecrosis, the HRs were 1.40 (95% CI, 1.12-1.75; P = .002), 0.99 (95% CI, 0.70-1.40; P = .96), and 1.36 (95% CI, 1.04-1.77; P = .02) per 100 IU/L increase in median AEA, respectively. No significant decrease in the risk of leukemic relapse was found: HR 0.88 per 100 IU/L increase in AEA (95% CI, 0.66-1.16; P = .35). In conclusion, these results emphasize that overall AspTox and relapse are not associated with AEA levels, yet the risk of pancreatitis and osteonecrosis increases with increasing AEA levels.

28 March 2022 in British Journal of Haematology
Verified
Journal Article
Closed access
LLLine Stensig Lynggaard
Line Stensig Lynggaard
GVGoda Vaitkeviciene
Goda Vaitkeviciene
CLCecilia Langenskiöld
Cecilia Langenskiöld
ALAnne Kristine Lehmann
Anne Kristine Lehmann
PLPäivi M. Lähteenmäki
Päivi M. Lähteenmäki
BABirgitte Klug Albertsen
Birgitte Klug Albertsen

29 January 2024 in Leukemia
Verified
Journal Article
Open access
PDF file
MDMerete Dam
Merete Dam
MCMaddalena Centanni
Maddalena Centanni
LFLena E. Friberg
Lena E. Friberg
DCDaniel Centanni
Daniel Centanni
MKMats O. Karlsson
Mats O. Karlsson
BABirgitte Klug Albertsen
Birgitte Klug Albertsen
Asparaginase is an essential component of acute lymphoblastic leukemia (ALL) therapy, yet its associated toxicities often lead to treatment discontinuation, increasing the risk of relapse. Hypersensitivity reactions include clinical allergies, silent inactivation, or allergy-like responses. We hypothesized that even moderate increases in asparaginase clearance are related to later inactivation. We therefore explored mandatory monitoring of asparaginase enzyme activity (AEA) in patients with ALL aged 1–45 years treated according to the ALLTogether pilot protocol in the Nordic and Baltic countries to relate mean AEA to inactivation, to build a pharmacokinetic model to better characterize the pharmacokinetics of peg-asparaginase and assess whether an increased clearance relates to subsequent inactivation. The study analyzed 1631 real-time AEA samples from 253 patients, identifying inactivation in 18.2% of the patients. This inactivation presented as mild allergy (28.3%), severe allergy (50.0%), or silent inactivation (21.7%). A pharmacokinetic transit compartment model was used to describe AEA-time profiles, revealing that 93% of patients with inactivation exhibited prior increased clearance, whereas 86% of patients without hypersensitivity maintained stable clearance throughout asparaginase treatment. These findings enable prediction of inactivation and options for either dose increments or a shift to alternative asparaginase formulations to optimize ALL treatment strategies.

1 November 2016 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
LLLine Stensig Lynggaard
Line Stensig Lynggaard
HMHanne V. Marquart
Hanne V. Marquart
EKEigil Kjeldsen
Eigil Kjeldsen
HMHans O. Madsen
Hans O. Madsen
HHHenrik Hasle
Henrik Hasle
A small group of children with acute lymphoblastic leukemia (ALL) have a preleukemic phase of pancytopenia followed by a period of spontaneous remission before the diagnosis (pre-ALL). A 6-year-old girl presented with pancytopenia, fever, and myelodysplasia. Following transient remission pre-B ALL was diagnosed 14 months later. Clonal B-lineage blasts at the period of pancytopenia were identified retrospectively. The interval between pre-ALL and ALL-diagnosis was longer than previously reported. The infection was clinically severe and might have induced a significant endogenous corticosteroids production resulting in the long-lasting remission. The case supports the adrenal and the Coley's toxin hypothesis in leukemogenesis.

9 March 2018 in Blood Advances
Verified
Journal Article
Open access
PDF file
AØAndreas K. Øvlisen
Andreas K. Øvlisen
AOAnders Oest
Anders Oest
MBMette D. Bendtsen
Mette D. Bendtsen
JBJohn Bæch
John Bæch
PJPreben Johansen
Preben Johansen
MSMarianne Tang Severinsen
Marianne Tang Severinsen
Key Points: sCR and non-sCR in acute myeloid leukemia are associated with different prognoses. Three lineage blood cell recoveries have independent impacts on prognosis.

13 August 2021 in Leukemia
Verified
Journal Article
Closed access
PDF file
LALiv Andrés-Jensen
Liv Andrés-Jensen
KGKathrine Grell
Kathrine Grell
CRCecilie Utke Rank
Cecilie Utke Rank
BABirgitte Klug Albertsen
Birgitte Klug Albertsen
RTRuta Tuckuviene
Ruta Tuckuviene
KSKjeld Schmiegelow
Kjeld Schmiegelow